MedImmune FluMist "complete response"
This article was originally published in Pharmaceutical Approvals Monthly
MedImmune plans to respond to its second "complete response" letter for FluMist before the end of August. The July 10 letter raises 24 manufacturing questions and 44 clinical questions relating to the influenza vaccine, including the issue of exacerbated rates of asthma and wheezing in patients 18 to 35 months of age. MedImmune is considering excluding the subpopulation from the indication as one way to address the problem, the company told a July 11 conference call. Increased reactogenicity in asthmatics was raised as an issue during a July 2001 advisory committee review. MedImmune does not expect to launch FluMist in time for the 2002 flu seaso
You may also be interested in...
There could be 28 notified body designations in total under the Medical Device Regulation by the end of 2021. But there is cause for concern over designations under the IVD Regulation, which are lagging far behind.
Swiss Health Providers Turn Heat On Federal Council: 12% Loss Of Medtech Products Likely On EU MRA Failure
A consortium of Swiss providers, patient groups and health care trade bodies is imploring the federal council to avert a looming patient care crisis in Switzerland if the EU MRA cannot be agreed.
China’s first domestically-developed recombinant protein vaccine for COVID-19 moves forward in late-stage trials in two countries.